Current and emerging "at-site" pain medications: A review

Journal of Pain Research

Volumn 4, Issue , 2011, Pages 279-286

  Rao, Praveen P N ^a   Mohamed, Tarek ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Cannabinoid receptors; Glial cells; Nonsteroidal anti inflammatory drugs; Opioids; P2X receptors; Transient receptor potential channels

Indexed keywords

EID: 84872006537     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S11308     Document Type: Review

References (71)

1. Anand KJS, Craig KD. New perspectives on the definition of pain. Pain. 1996;67(1):3-6.
2. Melnikova I. Pain market. Nat Rev Drug Dis. 2010;9(8):589-590.
3. Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008; 9(10):883-891.
4. Goucke RC. The management of persistent pain. Med J Aust. 2003; 178(9):444-447.
5. Helms JE, Barone CP. Physiology and treatment of pain. Crit Care Nurse. 2008;28(6):38-49.
6. Reichling DB, Levine JD. Pain and death: neurodegenerative disease mechanisms in the nociceptor. Ann Neurol. 2011;69(1):13-21.
7. Baron R. Neuropathic pain: a clinical perspective. Handb Exp Pharmacol. 2009;194:3-30.
8. Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth. 2010;105(Suppl 1):i69-i85.
9. Milan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;57(1):1-164.
10. Schaible HG. Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol. 2007;177:3-28.
11. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;5(Suppl): 1062-1067.
12. Bras M, Dordevic V, Grequrek R, Bulajic M. Neurobiological and clinical relationship between psychiatric disorders and chronic pain. Psychiatr Danub. 2010;22(2):221-226.
13. Marazziti D, Mungai F, Vivarelli L, Presta S, Dell'Osso B. Pain and psychiatry: a critical analysis and pharmacological review. Clin Pract Epidemiol Ment Health. 2006;2:31.
14. Lynch ME, Watson CPN. The pharmacotherapy of chronic pain: a review. Pain Res Manage. 2006;11(1):11-38.
15. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206-219.
16. Centers for Disease Control and Prevention. National Hospital Ambulatory Medical Care Survey (NHAMCS). Atlanta, GA: Centers for Disease Control and Prevention. Available from: http://www.cdc. gov/nchs/ahcd.htm. Accessed June 18, 2011.
17. Woodcock J. A difficult balance-pain management, drug safety, and the FDA. N Eng J Med. 2009;361(22):2105-2107.
18. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342:c7086.
19. Mendelson J, Flower K, Pletcher MJ, Galloway GP. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Exp Clin Psychopharmacol. 2008;16(5): 435-441.
20. Fox A, Bevan S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs. 2005;14(6): 695-703.
21. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol. 2001; 63(5):569-611.
22. Cheng Y, Hitchcock SA. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs. 2007;16(7):951-965.
23. Galieque S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54-61.
24. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive, subjective dose-response effects of acute oral {increment}9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology. 2002;164(1):61-70.
25. Robinson L, Goonawardena AV, Pertwee RG, Hampson RE, Riedel G. The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. Br J Pharmacol. 2007;151(5): 688-700.
26. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11(2):563-583.
27. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949.
28. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005;168:1-51.
29. Rahn EJ, Hohman AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotheraptics. 2009;6(4):713-737.
30. Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Patents. 2009;19(12): 1647-1673.
31. 2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol. 2011;162(2):428-440.
32. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A. 1999;96(25):14228-14233.
33. 2 receptor? Br J Pharmacol. 2006;149(2):145-154.
34. 2-cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003;100(18):10529-10533.
35. 2 cannabinoid receptor activity. J Med Chem. 2010;53(1):295-315.
36. 2 cannabinoid receptor activity. J Med Chem. 2008;51(6):1904-1912.
37. 2) agonists. J Med Chem. 2008;51(16):5019-5034.
38. Giblin GMP, O'Shaughnessy CT, Naylor A, et al. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem. 2007; 50(11):2597-2600.
39. 2 agonist for the treatment of chronic pain. J Med Chem. 2009;52(19):5785-5788.
40. 2 Cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series. J Med Chem. 2010; 53(22):7918-7931.
41. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Dis. 2009;8(1):55-68.
42. Romanovsky AA, Almeida MC, Garami A, et al. The transient receptor potential vanilloid-1 channel in thermoregulation: thermosensor it is not. Pharmacol Rev. 2009;61(3):228-261.
43. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007;76:387-417.
44. Levine JD, Haber NA. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007;1772(8):989-1003.
45. Premkumar LS. Targeting TRPV1 as an alternative approach to narcotic analgesic to treat chronic pain conditions. AAPS J. 2010;12(3):361-370.
46. Joshi NK, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med. 2009;15(1):14-22.
47. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today. 2009;14(1-2):56-67.
48. Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006;16(12): 3287-3291.
49. Doherty EM, Bannon AW, Bo Y, et al. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationship of 4-oxopyrimidines leading to the selection of a clinical candidate. J Med Chem. 2007;50(15): 3515-3527.
50. Wang HL, Katon J, Balan C, et al. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. J Med Chem. 2007;50(15):3528-3539.
51. Gomtsyan A, Bayburt EK, Schmidt RG, et al. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl) urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem. 2008;51(3):392-395.
52. Honore P, Chandran P, Hernandez G, et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain. 2009;142(1-2):27-35.
53. Rowbotham MC, Nothaft W, Duan WR, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011;152(5):1192-2000.
54. Westaway SM. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007;50(11):2589-2596.
55. Chizh BA, Illes P. P2X receptors and nociception. Pharmacol Rev. 2001;53(4):553-568.
56. Kennedy C, Assis TS, Currie J, Rowan EG. Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol. 2003;553(Pt 3):683-694.
57. Kennedy C. P2X receptors: targets for novel analgesics? Neuroscientist. 2005;11(4):345-356.
58. Burnstock G. Purinergic signaling and disorders of the central nervous system. Nat Rev Drug Dis. 2008;7(8):575-590.
59. Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol. 2009;71:333-359.
60. 7 in pain and inflammation. Purinergic Signal. 2007;3(1-2):163-169.
61. Gunosewoyo H, Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat. 2010;20(5):625-646.
62. Nelson DW, Gregg RJ, Kort ME, et al. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem. 2006;49(12):3659-3666.
63. Nelson DW, Sarris K, Kalvin DM, et al. Structure-activity relationship studies on Ń-aryl carbohydrazide P2X7 antagonists. J Med Chem. 2008;51(10):3030-3034.
64. Medrano AP, Donnelly-Roberts DL, Honore P, et al. Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain. J Med Chem. 2009;52(10):3366-3376.
65. Furber M, Alcaraz L, Bent JE, et al. Discovery of potent and selective adamantane-based small-molecule P2X7 receptor antagonists/ interleukin-1β inhibitors. J Med Chem. 2007;50(24):5882-5885.
66. Guile SD, Alcaraz L, Birkinshaw TN, et al. Antagonists of the P2X7 receptor. From lead identification to drug development. J Med Chem. 2009;52(10):3123-3141.
67. Watkins LR, Maier SF. Targeting glia to control clinical pain: an idea whose time has come. Drug Discov Today. 2004;1(1):83-88.
68. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10(1):23-36.
69. McMahon SB, Malcangio M. Current challenges in glia-pain biology. Neuron. 2009;64(1):46-54.
70. Svensson CI, Brodin E. Spinal astrocytes in pain processing: nonneuronal cells as therapeutic targets. Mol Interv. 2010;10(1):25-38.
71. Beggs S, Salter MW. Microglia-neuronal signaling in neuropathic pain hypersensitivity 2.0. Curr Opin Neurobiol. 2010;20(4):474-480.